Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lidocaine

This article was originally published in The Tan Sheet

Executive Summary

Topical cream is "effective and safe" for acute migraine pain in 40-person, placebo-controlled parallel trial, F. Freitag, Diamond Headache Clinic, Chicago, et al., report in poster presented at the American Society for Clinical Pharmacology & Therapeutics annual meeting in Orlando March 6-10. Delivered via a patch, lidocaine cream demonstrated "significant" pain reduction among migraine sufferers after eight hours. On a 10-point scale, baseline pain fell from a mean of 6.93 to 5.51 after two hours and to 1.70 after eight. No significant adverse events were observed, the researchers report. Sponsor Epicept, an Englewood Cliffs, N.J.-based pharmaceutical firm exploring pain management, plans to seek FDA approval of lidocaine products indicated for back ache, headache and migraine. The firm intends to conduct additional Phase II studies and a Phase III trial of 500-600 people by early 2002
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel